Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Blood (2025) 146 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2025-3806

Published: 2025

Journal Articles

Transcriptomic analysis of CD34⁺ cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis

Simona Bernardi, Luca Garuffo, Mirko Farina, Giulia Pozzi, Livia Micaela Pasini, Samuele Cortellazzi, Alessandro Leoni, Orsola Di Martino, Francesca Arciprete, Maria Zingariello, Marco Vitale, Domenico Russo, Cecilia Carubbi, Elena Masselli

Blood (2025) 146 (Supplement 1): 5535.

https://doi.org/10.1182/blood-2025-5535

Published: 2025

Journal Articles

Infectious complications in elderly newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: Comparison with a historical control group treated with intensive chemotherapy

Chiara Cattaneo, Lisa Colleoni, Mirko Farina, Laura Donatoni, Lorenzo Masina, Simone Maifredi, Erika Borlenghi, Francesca Federico, Alessandra Tucci, Michele Malagola

Blood (2025) 146 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2025-6895

Published: 2025

Journal Articles

Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study

Mirko Farina, Filippo Bergamelli, Daniele Avenoso, Vera Radici, Andrea Guerini, Ludovica Pegurri, Enrico Morello, Gabriele Magliano, Beatrice Battaglio, Simone Maifredi, Sofia Terlizzi, Rachele De Domenico, Silvia Zanon, Alessandro Leoni, Simona Bernardi, Stefano Maria Magrini, Michela Buglione Di Monale e Bastia, Domenico Russo, Michele Malagola

Blood (2025) 146 (Supplement 1): 4208.

https://doi.org/10.1182/blood-2025-4208

Published: 2025

Journal Articles

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

Blood (2025) 146 (Supplement 1): 6279.

https://doi.org/10.1182/blood-2025-6279

Published: 2025

Journal Articles

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 6278.

https://doi.org/10.1182/blood-2025-6278

Published: 2025

Journal Articles

Stimulated CAR-T cells from non-Hodgkin lymphomas patients engage and activate monocytes via extracellular vesicles

Besjana Xhahysa, Simona Bernardi, Mirko Farina, Ilaria Grossi, Luca Garuffo, Rosalba Ferraro, Alessandro Leoni, Alessia Cavalleri, Silvia Mutti, Federica Trenta, Federica Re, Enrico Morello, Daniele Avenoso, Piera Balzarini, Alessandro Salvi, Michele Malagola, Domenico Russo

Blood (2025) 146 (Supplement 1): 5890.

https://doi.org/10.1182/blood-2025-5890

Published: 2025

Journal Articles

Beyond presence: Clinical relevance of FLT3-ITD length and location in Acute Myeloid Leukemia (AML)

Alessandro Leoni, Mirko Farina, Diego Bertoli, Carlotta Giupponi, Erika Borlenghi, Besjana Xhahysa, Luca Garuffo, Alessia Cavalleri, Federica Trenta, Federica Re, Silvia Mutti, Daniele Avenoso, Michele Malagola, Domenico Russo, Roberto Bresciani, Giorgio Biasiotto, Simona Bernardi

Blood (2025) 146 (Supplement 1): 7023.

https://doi.org/10.1182/blood-2025-7023

Published: 2025

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

Psychosocial well-being in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their caregivers: A prospective study

Alessandro Leoni, Elsa Cavagna, Enrico Morello, Giulia Benedini, Giulia Brambilla, Daniele Avenoso, Simona Bernardi, Mirko Farina, Gabriele Magliano, Vera Radici, Domenico Russo, Michele Malagola

Blood (2025) 146 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2025-2497

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Blood (2024) 144 (Supplement 1): 7823.

https://doi.org/10.1182/blood-2024-199498

Published: 2024

Journal Articles

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Blood (2024) 144 (Supplement 1): 3131.

https://doi.org/10.1182/blood-2024-199720

Published: 2024

Journal Articles

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Blood (2024) 144 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2024-207660

Published: 2024

Journal Articles

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Blood (2024) 144 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2024-199961

Published: 2024

Journal Articles

Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis

Mirko Farina, Marco Chiarini, Sofia Terlizzi, Anna Galvagni, Simona Bernardi, Alessandro Leoni, Enrico Morello, Vera Radici, Gabriele Magliano, Lorenzo Masina, Marco Galli, Federica Re, Virginia Quaresima, Daniele Moratto, Duilio Brugnoni, Michele Malagola, Nicola Polverelli, Domenico Russo

Blood (2024) 144 (Supplement 1): 7372.

https://doi.org/10.1182/blood-2024-209545

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Transcriptomic analysis of CD34⁺ cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis

Infectious complications in elderly newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: Comparison with a historical control group treated with intensive chemotherapy

Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Stimulated CAR-T cells from non-Hodgkin lymphomas patients engage and activate monocytes via extracellular vesicles

Beyond presence: Clinical relevance of FLT3-ITD length and location in Acute Myeloid Leukemia (AML)

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Psychosocial well-being in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their caregivers: A prospective study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only